NVA237 Versus Placebo 12-week Efficacy Study
Launched by NOVARTIS PHARMACEUTICALS · Oct 16, 2012
Trial Information
Current as of May 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • 1. Patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011).
- • 2. Patients with Forced Expiratory Volume in one second (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/ Forced Vital Capacity (FVC) \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.
- • 3. Current or ex-smokers with at least 10 cigarette pack years smoking history.
- Exclusion criteria:
- • 1. Patients with a history of long QT syndrome, with a prolonged QTc measured during screening, or patients who have a clinically significant ECG abnormality at screening.
- • 2. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- • 3. Pregnant or nursing (lactating) women. Women of childbearing potential unless using an effective method of contraception.
- • 4. Patients who in the judgment of the investigator, would be at potential risk if enrolled into the study.
- • 5. Patients who have a clinically significant concomitant disease at screening, including but not limited to clinically significant laboratory abnormalities, clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with uncontrolled diabetes, which could interfere with the assessment of the efficacy and safety of the study treatment.
- • 6. Patients with a body mass index (BMI) of more than 40 kg/m2.
- • 7. Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta-2 agonists, or sympathomimetic amines.
- • 8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or patients with a high blood eosinophil count during screening.
- • Other protocol-defined inclusion/exclusion criteria may apply.
About Novartis Pharmaceuticals
Novartis Pharmaceuticals is a global healthcare company dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovation, Novartis engages in the research, development, and commercialization of a broad range of therapies across various therapeutic areas, including oncology, cardiology, dermatology, and neuroscience. The company is committed to advancing scientific knowledge and patient care through clinical trials that prioritize safety and efficacy. Novartis leverages cutting-edge technology and collaborative partnerships to address unmet medical needs and deliver transformative treatments that enhance patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Fountain Valley, California, United States
Fullerton, California, United States
Miami, Florida, United States
Spartanburg, South Carolina, United States
Arlington, Texas, United States
Winter Park, Florida, United States
Raleigh, North Carolina, United States
Waco, Texas, United States
Pompano Beach, Florida, United States
Tamarac, Florida, United States
Charlotte, North Carolina, United States
Union, South Carolina, United States
Tucson, Arizona, United States
Columbia, South Carolina, United States
Simpsonville, South Carolina, United States
Jasper, Alabama, United States
Riverside, California, United States
Pensacola, Florida, United States
South Miami, Florida, United States
Tampa, Florida, United States
Gaffney, South Carolina, United States
Greenville, South Carolina, United States
Port Orange, Florida, United States
Homewood, Alabama, United States
Hialeah, Florida, United States
Clearwater, Florida, United States
Beaumont, Texas, United States
Dallas, Texas, United States
Shelby, North Carolina, United States
Easley, South Carolina, United States
Sarasota, Florida, United States
Seneca, South Carolina, United States
Charleston, South Carolina, United States
Defuniak Springs, Florida, United States
Ninety Six, South Carolina, United States
Fort Lauderdale, Florida, United States
Brandon, Florida, United States
*See Various Dept.'S*, Arizona, United States
San Diego, California, United States
Edgewater, Florida, United States
Summerfield, Florida, United States
Las Vegas, Nevada, United States
Rock Hll, South Carolina, United States
Amarillo, Texas, United States
Huntsville, Texas, United States
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials